Avenzo Therapeutics

At Avenzo Therapeutics, our success is driven by the dedication, passion, and innovation of our incredible team. For #EmployeeAppreciationDay, we take a moment to express our gratitude to our team for their commitment to our common purpose – developing #oncology therapies that make a difference in the lives of patients. Thank you, #TeamAvenzo!?

We’re excited to welcome Justin Drohan, CPA, MAcc, our senior director and Controller! His strategic financial leadership along with his track record of building and leading high-performing teams will be invaluable as we continue to grow #TeamAvenzo and advance our pipeline of potential best-in-class #oncology therapies.

Please join us in giving a warm welcome to Robyn Gavin, the newest member of #TeamAvenzo! Robyn joins us as associate director, Medical Writing, and we look forward to having her vital support in our efforts to advance innovative therapies that aim to deliver improved medicines to #cancer patients.??

We’re delighted to welcome two new members to #TeamAvenzo!?Brittny Dixon joins as associate director, Clinical Data Programming, contributing her expertise in clinical data management to drive meaningful results.?Jasmine Pham joins us as senior director, Quality Assurance, bringing extensive experience in ensuring high-quality standards across clinical and operational processes. We look forward to having Brittny and Jasmine on board as we advance our pipeline of next-generation #oncology therapies.?

Join us in welcoming Maria E. to #TeamAvenzo as our senior director, Clinical Operations! We’re excited to have Maria on our team as we continue to advance our pipeline of #oncology therapies that have the potential to make a meaningful difference in the lives of patients with high unmet medical needs.

Today, we announced an exclusive?global?license?(excluding Greater China)?with Duality Biologics to develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate.?We look forward to working side by side with DualityBio to?continue advancing this program and plan to initiate?a first-in-human clinical study this year. Read the full press release to learn more: https://bit.ly/3PnK0qG?#ADC #Collaboration #Oncology

We’re delighted to welcome Blake Benner as executive director, Alliance Management, and Jessica L. Coleman as associate director, Clinical Outsourcing to our growing team.?Their knowledge and experience will help support our mission of advancing potentially differentiated #oncology therapies to transform cancer treatment. Welcome to #TeamAvenzo!?

Today, we announced the appointment of Patrick Machado, J.D. to our Board of Directors. Mr. Machado’s more than 20 years of global #biotech management and board experience will be highly beneficial as we continue to build and advance our pipeline of #oncology therapies to help patients fight #cancers with a high unmet medical need.?? ? Read the full press release: https://bit.ly/3CLqW2q

Exclusive: Avenzo Therapeutics is joining the growing trend of US biotechs in-licensing assets from China-based drug developers as the San Diego startup has inked a deal for VelaVigo's Nectin-4/TROP2 bispecific antibody-drug conjugate. Avenzo also brought in an additional ~$39 million and promoted Scott Lipman to chief business officer. Avenzo is searching for more ADCs as it plans to have multiple experimental medicines in the clinic next year ahead of a potential IPO in late 2025 or early 2026, CEO Athena Countouriotis told Endpoints News #adc #antibodydrugconjugate #biotech #licensingdeal #chinabiotech #nectin4 #trop2 #oncologydrugdevelopment #avenzo #velavigo

Today marks an important step in our growth as we announce the closing of the final tranche of a Series A/A-1 #financing, bringing our total capital raised to $386M. Additionally, we entered an exclusive option agreement with VelaVigo to develop, manufacture & commercialize a potential first-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (#ADC) for multiple solid tumors, including metastatic urothelial #cancer.? ? Lastly, we are proud to share that Scott Lipman, MBA, has received the well-deserved promotion to Chief Business Officer. These significant milestones build on our continued momentum as we continue to build and advance a pipeline of best- or first-in-class #oncology therapies. Read the full press release here: https://bit.ly/3AMWkgs?